March 26, 2024Open Access

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Atezolizumab plus bevacizumab (atezo-bev) has been recommended for advanced hepatocellular carcinoma (HCC). High-dose external beam radiotherapy (RT) is recognized for its excellent local tumor control. The efficacy and safety of concurrent atezo-bev with RT for highly advanced HCC has been minimally explored.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Su et al. (Tue,) studied this question.

synapsesocial.com/papers/68e7242fb6db64358769dc3f — DOI: https://doi.org/10.1093/oncolo/oyae048

Authors

Chung‐Wei Su

Chang Gung University

Wei Teng

Harbin Medical University

Eric Yi-Liang Shen

Chang Gung Memorial Hospital

Journals

The Oncologist

Actions

Institutions

Chang Gung University

Chang Gung Memorial Hospital

Linkou Chang Gung Memorial Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion